Population Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients Treated for Hepatitis C Virus Genotype 2/3

Yu, Jing; Sun, Haiying; Pang, Maria; Chuang, Wan–Long; Sarin, Shiv Kumar; Flisiak, Robert; Stein, Daniel S.

doi:10.2174/22113525113119990108

Search citation statements

Order By: Relevance

Paper Sections

Select...

Albumin-based Products1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, increased rates of pulmonary adverse events were noted with Albinterferon, including interstitial lung disease, compared with those seen with PEGylated IFN-α. Many clinical trials are currently underway to evaluate the dosage regimen and new treatment options for this preparation, and findings are now being accumulated [ 45 , 46 , 47 ].…”

Section: Albumin-based Productsmentioning

confidence: 99%

Potential Use of Biological Proteins for Liver Failure Therapy

et al. 2015

View full text Add to dashboard Cite

Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.

show abstract

Section: Albumin-based Productsmentioning

confidence: 99%